ProMIS Neurosciences to Present at 20th Annual Global Investment Conference
TORONTO and CAMBRIDGE, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that it will be featured as a presenting company at the 20 th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.Wainwright & Co. The conference is being held on September 4-6, 2018 at the St Regis New York Hotel in New York City.
Eugene Williams, Executive Chairman of ProMIS Neurosciences will provide a corporate overview in the Fontainebleau Foyer on Thursday, September 6, 2018, at 2:10 p.m. EDT, and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor and would like to attend the Company's presentation please visit www.rodmanevents.com to register for the conference. Once your registration is confirmed, you will be able to log into the conference website to request a one-on-one meeting.
A live webcast of ProMIS' presentation may be accessed through the company website www.promisneurosciences.com , via this link and from the conference site at www.rodmanevents.com . Please log on to the webcast prior to the scheduled event to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on ProMIS' website following the presentation.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS(TM) and Collective Coordinates- to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information please visit us at: www.promisneurosciences.com
For media inquiries, please contact:
Tel. 617 921-0808
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via GlobeNewswire